- |||||||||| EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis (clinicaltrials.gov) - Apr 24, 2024
P3, N=204, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- |||||||||| EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
Trial primary completion date: Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis (clinicaltrials.gov) - Oct 27, 2022
P3, N=204, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
Trial primary completion date: Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis (clinicaltrials.gov) - Jul 23, 2022
P3, N=204, Recruiting,
Trial primary completion date: Dec 2022 --> Dec 2023 Trial primary completion date: Dec 2023 --> Dec 2022
- |||||||||| EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
Enrollment open, Trial completion date, Trial primary completion date: EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2) (clinicaltrials.gov) - Dec 3, 2021
P3, N=284, Recruiting,
Trial primary completion date: Dec 2023 --> Dec 2022 Not yet recruiting --> Recruiting | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Nov 2021
- |||||||||| EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
Trial completion date, Trial primary completion date: Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis (clinicaltrials.gov) - Jul 14, 2021
P3, N=204, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Nov 2021 Trial completion date: Mar 2021 --> Jan 2024 | Trial primary completion date: Mar 2021 --> Dec 2023
- |||||||||| EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
Trial completion date, Trial initiation date, Trial primary completion date: EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2) (clinicaltrials.gov) - Nov 1, 2020
P3, N=284, Not yet recruiting,
Trial completion date: Mar 2021 --> Jan 2024 | Trial primary completion date: Mar 2021 --> Dec 2023 Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: Apr 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Jul 2021
- |||||||||| EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
Enrollment change: EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2) (clinicaltrials.gov) - May 1, 2020
P3, N=240, Not yet recruiting,
Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: Apr 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Jul 2021 N=150 --> 240
|
